Rotator Cuff Tear
Conditions
Keywords
Massive Rotator Cuff Tear, Local anesthesia, Sub-acromial spacer
Brief summary
The study objective is to assess the feasibility, efficacy and safety of the InSpace™ Device implantation in a surgical procedure under local anesthesia using arthroscopic and/or fluoroscopic visualization of the affected shoulder.
Detailed description
A single arm, open-label, prospective, study to assess the feasibility, efficacy and safety of InSpace™ device implantation in a procedure under local anesthesia for a treatment of subjects with massive, irreparable rotator cuff tear. Subjects with radiological confirmed massive RCT who are eligible per inclusion/exclusion criteria, will be enrolled for the study treatment. Subjects will undergo surgical intervention under local anesthesia , fluoroscopic and/ or arthroscopic visualization of InSpace™ implantation. Subjects will then be followed for safety and efficacy for a 24 months following the implantation. The study objective is to assess the feasibility, efficacy and safety of the InSpace™ Device implantation in a surgical procedure under local anesthesia using arthroscopic and/or fluoroscopic visualization of the affected shoulder. The efficacy will be assess by using Constant and ASES outcome score The Constant and the ASES will be completed by the investigator at each study visit .The patient will complete the patient self-evaluation part of the ASES at each study visit. The Safety assessment will be conducted by collecting all device related AEs/SAEs throughout the entire study period.
Interventions
DEVICEInSpace Implantation
InSpace device Implantation
Sponsors
OrthoSpace Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
Open Label
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 50 or older. 2. Positive diagnostic MRI of the affected shoulder indicating full thickness massive irreparable RCT of at least 5cm in diameter (according to Cofield classification) including fatty infiltration grade III or IV (according to classification of Goutallier). 3. Persistent pain and failure of non-operative treatment of the affected shoulder for at least 3 months.
Exclusion criteria
1. Known allergy to the balloon material 2. Evidence of significant osteoarthritis or cartilage damage in the shoulder 3. Evidence of gleno-humeral instability 4. Evidence of major joint trauma, infection, or necrosis in the shoulder 5. Major medical condition or known drug or alcohol abuses that could affect quality of life and influence the results of the study. 6. Concurrent participation in any other invasive clinical study one month prior to enrollment to the study and during the entire study period. 7. Subjects with worker's compensation claims or other litigation claims related to the shoulder being treated in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in total shoulder outcome scores (Constant and ASES) | 6 months post implanatation | Change in total shoulder outcome scores (Constant and ASES)at 6 month post implantattion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Total Shoulder scores | up to 24 months post implantation | Change in Total Shoulder scores and improvement compare to baseline at each time point (6W, 3m, 12m and 24m). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety Assessment | 24 months post implantation | The Safety assessment will include all device related AEs/SAEs throughout the entire study period. |
Countries
Italy
Outcome results
None listed